10 The KEYNOTE‐604 study demonstrated that in the first‐line treatment of patients with ES‐SCLC, pembrolizumab plus etoposide and platinum (EP) improved PFS in patients compared to placebo plus EP, but overall survival only showed a trend toward benefit and did not reach the threshold of significance (mPFS: 4.5 vs. 4.3 months, mOS: 10.8 vs. 9.7 months). 11 It is believed that SCLCs are homogeneous and are characterized almost by functional inactivation of the tumor suppressors RB1 and TP53. 12 , 13 However, four transc
1
—
—